Edwards Lifesciences (NYSE:EW) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Edwards Lifesciences (NYSE:EW) from a hold rating to a buy rating in a research note issued to investors on Saturday,Wall Street Zen reports.

A number of other analysts have also recently weighed in on the stock. UBS Group initiated coverage on shares of Edwards Lifesciences in a research note on Tuesday, July 28th. They issued a “buy” rating and a $110.00 price objective for the company. TD Cowen reissued a “buy” rating on shares of Edwards Lifesciences in a research report on Tuesday, July 21st. Evercore reaffirmed an “outperform” rating and set a $100.00 price objective on shares of Edwards Lifesciences in a research note on Monday, July 6th. Piper Sandler restated an “overweight” rating and issued a $101.00 target price (up from $100.00) on shares of Edwards Lifesciences in a research note on Friday, July 24th. Finally, BTIG Research restated a “buy” rating and issued a $110.00 price objective on shares of Edwards Lifesciences in a research report on Friday. Seventeen investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $100.27.

Edwards Lifesciences Stock Performance

Shares of EW stock opened at $85.58 on Friday. The firm has a market cap of $49.27 billion, a P/E ratio of 49.18, a PEG ratio of 2.21 and a beta of 0.85. The stock’s 50-day moving average is $88.97 and its two-hundred day moving average is $85.84. Edwards Lifesciences has a fifty-two week low of $72.30 and a fifty-two week high of $96.29. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.52 and a quick ratio of 3.77.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.74 by $0.04. The firm had revenue of $1.74 billion for the quarter, compared to the consensus estimate of $1.70 billion. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The firm’s revenue was up 13.6% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.67 earnings per share. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Analysts predict that Edwards Lifesciences will post 3 earnings per share for the current fiscal year.

Insider Activity

In other news, VP Annette Brüls sold 2,644 shares of Edwards Lifesciences stock in a transaction dated Friday, August 28th. The stock was sold at an average price of $89.98, for a total transaction of $237,907.12. Following the transaction, the vice president owned 17,984 shares in the company, valued at $1,618,200.32. The trade was a 12.82% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Daniel Lippis sold 619 shares of the company’s stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $92.03, for a total transaction of $56,966.57. Following the completion of the transaction, the vice president owned 40,034 shares of the company’s stock, valued at $3,684,329.02. This trade represents a 1.52% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 5,664 shares of company stock worth $511,918 in the last 90 days. Corporate insiders own 0.31% of the company’s stock.

Institutional Investors Weigh In On Edwards Lifesciences

Several hedge funds and other institutional investors have recently added to or reduced their stakes in EW. California State Teachers Retirement System grew its position in shares of Edwards Lifesciences by 9,187.8% during the 2nd quarter. California State Teachers Retirement System now owns 80,962,062 shares of the medical research company’s stock worth $7,323,828,000 after purchasing an additional 80,090,362 shares in the last quarter. BlackRock Inc. bought a new position in shares of Edwards Lifesciences in the 2nd quarter valued at $5,318,092,000. Bank of New York Mellon Corp acquired a new position in Edwards Lifesciences during the second quarter worth about $1,274,082,000. Norges Bank acquired a new position in Edwards Lifesciences during the 4th quarter worth approximately $803,686,000. Finally, Bank of America Corp DE bought a new position in shares of Edwards Lifesciences in the 2nd quarter valued at $605,397,000. 79.46% of the stock is currently owned by institutional investors and hedge funds.

About Edwards Lifesciences

Edwards Lifesciences Corporation (NYSE:EW) is a medical technology company focused on therapies for structural heart disease. Its products are designed to treat conditions affecting the heart valves and related cardiovascular structures, helping patients with diseases such as aortic stenosis, mitral regurgitation and tricuspid valve disorders.

The company’s portfolio includes transcatheter aortic valve replacement systems, including its SAPIEN platform, as well as transcatheter mitral and tricuspid therapies and surgical heart valve products.